Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > TLT MGT Contact the Can Goverment , Corvid funding and help
View:
Post by Thor6570 on Oct 08, 2020 6:12am

TLT MGT Contact the Can Goverment , Corvid funding and help

McMaster receives $1M for infectious disease research

 

The Ontario government is providing $1 million to McMaster University for antimicrobial research and infectious disease management.

The money will be used to create a chemical library that will help develop new drugs against infectious diseases, along with creating online learning programs to help researchers in other fields transition to infectious disease management.

“At the core of McMaster’s research is a vast knowledge that spans all disciplines and this is really going to be essential for us to combat the current COVID crisis and future pandemics,” said Karen Mossman, McMaster’s associate vice-president of research and a specialist in virology and immunology.

Infectious diseases, such as tuberculosis, pneumonia and food-borne illnesses, are becoming harder to treat because of antibiotic resistance, while other infectious diseases, such as COVID-19, don’t have any effective treatments yet.

“COVID-19 has reminded the world of its vulnerability to infectious diseases, and McMaster is working to ensure that, as a global society, we are able to address that vulnerability and prepare ourselves effectively for the next outbreak,” said McMaster president David Farrar.

Drugs are made up of building blocks and figuring out which pieces fit together best to fight an illness without causing harmful side effects can be a time-consuming process of trial and error. The new chemical compound library will allow the building blocks to be put together in new ways in the hope of finding effective treatments.

In addition, McMaster hopes to entice researchers from other fields to the realm of infectious diseases by creating online learning platforms.

“What we’ve realized is that there are a lot of highly skilled people out there who have skills in other areas but would like to transition into infectious disease research, but they lack some of the basic background,” said Gerry Wright, director of McMaster’s Michael G. DeGroote Institute for Infectious Disease Research.

“We need economists, we need social scientists, we need engineers, we need clinicians,” he added.

Ross Romano, Ontario’s minister of colleges and universities, called McMaster’s research achievements “phenomenal.”

“The work that McMaster is doing is continually putting our province on the map.”

Comment by NeilPaert74 on Oct 08, 2020 11:33am
Thor, We'll know via Dr. Coombs in Nov. if this is a dry well. IF his research shows what we think then yes! TLT needs to send someone to sit down with the CDN government, along with Dr. Coombs to, to request beaucoup research $$. Hopefully TLT can get some $$ of their own this way, not just through U of M. 
Comment by langosta1 on Oct 08, 2020 12:05pm
You would think that with all the research money that the government splashes around at least a little bit of spaghetti would stick to the TLT wall.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250